Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention

Gene Regulation and Systems Biology

Volumn 2008, Issue 2, 2008, Pages 21-42

  Benbrook, Doris M ^a   Lightfoot, Stan ^a   Ranger Moore, James ^b   Liu, Tongzu ^a   Chengedza, Shylet ^a   Berry, William L ^a   Dozmorov, Igor ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Carcinogenesis; Chemoprevention; Endometrial cancer; Heteroarotinoid; Karyometric analysis; Microarrays

Indexed keywords

ANTINEOPLASTIC AGENT; DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; INHIBIN A; MYC PROTEIN; PROTEIN C JUN; PROTEIN P53; SOMATOMEDIN C RECEPTOR; SULFUR CONTAINING HETEROAROTINOID A2; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL MODEL; CANCER PREVENTION; CARCINOGENESIS; CELL NUCLEUS; CLONOGENIC ASSAY; CLUSTER ANALYSIS; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARYOMETRY; MICROARRAY ANALYSIS; ORGAN CULTURE; PHENOTYPE; PROTEIN SECRETION; SYSTEMS BIOLOGY; VALIDATION PROCESS;

EID: 66849092433     PISSN: None     EISSN: 11776250     Source Type: Journal    
DOI: 10.4137/grsb.s344     Document Type: Article

References (123)

1. Ahmad, T. and Famie, G. 2004. The mitogenic action of insulin-like growth factor I in normal human mammary epithalial cells requires the epidermal growth factor receptor tyrosine kinase. J. Biol. Chem., 279:1713-19.
2. Arnott, C.H., Scott, K.A., Moore, R.J. et al. 2002. Tumour necrosis factor-alpha mediates tomour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene, 21:4728-38.
3. Arora, A., Siddiqui, I.A. and Shukla, Y. 2004. Modulation of p53 in 7,12-dimethylhenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Molecular Cancer Therapeutics, 3:1459-66.
4. Bamberger, A.M., Milde-Langosch, K., Rossing, E. et al. 2001. Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. Journal of Cancer Research and Clinical Oncology, 127:545-50.
5. Benaud, C.M. and Dickson, R.B. 2001. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc. Oncogene, 20:4554-61.
6. Benbrook, D. 2006. Organotypic cultures represent tumor microenvironment for drug testing. Drug Discovery Today, 3:143-8.
7. Benbrook, D.M. 2002. Refining retinoids with heteroatoms. Minireviews in Med. Chem., 2:271-7.
8. Benbrook, D.M., Kamelle, S.A., Guruswamy, S.B. et al. 2005. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor antagonists. Inu New Drugs, 23:417-28.
9. Benbrook, D.M., Subramanian, S., Gale, J.B. et al. 1998. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. J. Med. Chem., 41:3753-7.
10. Benjamini, Y. and Hochberg, Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Statist. Soc. B., 57:289-300.
11. Biobase: http://www.biobase.de/pages
12. Bläuer, M., Heinonen, P.K., Martikainen, P.M. et al. 2005. A novel organo-typic culture model for normal human endometrium: regulation of epithelial cell proliferation by estradiol and medroxyprogesterone acetate. Hum. Reprod., 20:864-71.
13. Brenner, D.A., O'hara, M., Angel, P. et al. 1989. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature, 337:661-3.
14. Broaddus, R.R. and Lu, K.H. 2006. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Frontiers in Bioscience, 11:2077-80.
15. Bulletti, C., De Ziegler, D., Albonetti, A. et al. 1998. Paracrine regulation of menstruation. J. Reprod. Imm., 39:89-104.
16. Burchardt, E.R., Hein, R. and Bosserhoff, A.K. 2003. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clinical and Experimental Dermatology, 28:515-20.
17. Burgaud, J.L. and Baserga, R. 1996. Intracellular transactivation of the insulin-like growth factor 1 receptor by an epidermal growth factor receptor. Experimental Cell. Research, 223:412-9.
18. Buyukbayram, H. and Arslan, A. 2002. Value of tenascin-C content and association with clinicopathological parameters in uterine cervical lesions. Int. J. Cancer, 100:719-22.
19. Cai, X., Carlson, J., Stoicov, C. et al. 2005. Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice. Gastroenterology, 128:1937-52.
20. Camirand, A., Zakikhani, M., Young, F. et al. 2005. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research, 7:R.570-9.
21. Ceballos, E., Delgado, M.D., Gutierrez, P. et al. 2000. c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene, 19:2194-204.
22. Chakravarti, A., Loeffler, J.S. and Dyson, N.J. 2002. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Research, 62:200-7
23. Chen, C-C., Chow, M.-P., Huang, W.-C. et al. 2004. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB.: structure-activity relationships. Molecular Pharmacology, 66:683-93.
24. Chengedza, S., Liu, T. and Benbrook, D.M. 2007. SHetA2 Effects on Thymidine Phosphorylase and NF-κB. activity. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA USA.
25. Chiang, D.Y., Brown, P.O. and Eisen, M.B. 2001. Visualizing associations between genome sequences and gene expression data using genoma-mean expression profiles. Bioinformatics, 17:S49-55.
26. Chiquet-Ehrismann, R. and Chiquet, M. 2000: 2003. Tenascins regulation and putative functions during pathological stress. J. Pathol., 488-499.
27. Chun, K.-H., Benbrook, D.M., Berlin, K.D. et al. 2003. Induction of apoptosis in head and neck squamous cell carcinoma (HNSCC) cell lines by heteroarotinoids through a mitochondrial dependent pathway. Cancer Res., 63:3826-32.
28. Collins, M.D. and Bao, G.E. 1999. Teratology of retinoids. Ann. Rev. Pharmacol. Toxicol., 39:399-30.
29. Conner, E.A., Lemmer, E.R., Omori; M. et al. 2000. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene, 19:5054-62.
30. Coulouarn, C., Gomez-Quiroz, L.E., Lee, J.-S. et al. 2006. Oncogene-specific gene expression signatures al preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology, 44:1003-11.
31. Dhar, A., Liu, S., Klucik, J. et al. 1999. Synthesis and structure-activity relationships of nitrogen heteroarotinoids. J. Med. Chem., 42:3602-14.
32. Diab, A.M., Tawfeek, T.A., Moeity F. et al. 2006a. Mutations in exons 6 and 7 of TP53 gene correlate positively with serum tumor necrosis factor alpha independent of microsatellite instability in BAT26 gene in Egyptian patients with endometrial carcinoma. International Journal of Biological Markers, 21:184-9.
33. Diab, A.M., Tawfeek, T.A.S., Moeity, F. et al. 2006b. Mutations in exons 6 and 7 of TP53 gene correlate positively with serum tumor necrosis factor alpha independent of microsatellite instability in BAT26 gene in Egyptian patients with endometrial carcinoma. International Journal of Biological Markers, 21:184-9.
34. Dong, Y., Li, T., Liang, Y. et al. 2004a. [Human telomerase P53 estrogen and progesterone receptor expression in endometrial carcinoma]. Beijing da Xue Xue Bao Yi Xue Ban/Journal of Peking University Health Sciences, 36:61-5.
35. Dong, Y., Li, T., Wang, Y. et al. 2004b. [Expression of human telomerase reverse transcriptase and c-myc transcripts in endometrial carcinoma and its precursors]. Chung-Hua Ping Li Hsueh Tsa Chih - Chinese Journal of Pathology, 33:40-3.
36. Dozmorov, I. and Centola, M. 2003a. An associative analysis of gene expression array data. Bioinformatics, 19:204-41.
37. Dozmorov, I., Knowlton, N., Tang, Y. et al. 2004a. Statistical monitoring of weak spots for improvement of normalization and ratio estimates in microarrays. BMS Bioinformatics, 5:53.
38. Dozmorov, I., Knowlton, N., Tang, Y. et al. 2004b. Hypervariable genes - experimental error or hidden dynamics. Nucleic. Acids Res., 32:e147.
39. Dozmorov, I., Saban, M.R., Gerard, N.P. et al. 2003b. Neurokinin 1 receptors and neprilysin modulation of mouse bladder gene regulation. Physiol. Genomics, 12:239-50.
40. Dozmorov, I., Saban, M.R., Knowlton, N. et al. 2003c. Connective molecular pathways of experimental bladder inflammation. Physiol. Genomics, 15:209-22.
41. Dozmorov, I.M., Centola, M., Knowlton, N. et al. 2005. Mobile-classification in microarray experiments. Scand. J. Immunol., 62 (Suppl. 1):84-91.
42. Esposito, I., Penzel, R., Chaib-Harrireche, M. et al. 2006. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. Journal of Pathology. 208:673-85.
43. Evans, J.R.., Mitchell, S.A., Spriggs, K.A. et al. 2003. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene, 22:8012-20.
44. Fotovati, A., Fujii, T., Yamaguchi, M. et al. 2006. 17Beta-estradiol induces down-regulation of Cap43/NDRG1/Drg-1, a putative differentiation-related and metastasis suppressor gene, in human breast cancer cells. Clinical Cancer Research, 12:3010-8.
45. Geary, C.P. 1984. Carcinogen-induced granulosa cell tumours in NZC/B1 mice. Pathol., 16:131-5.
46. Grandori, C., Cowley, S.M., James, L.P. et al. 2000. The Myc/Max/Mad network and the transcriptional control of cell behavior. Ann. Rev. Cell. Dev. Biol., 16.653-99.
47. Gray, K., Bullock, B., Dickson, R. et al. 1997. Mechanisms of DES carcinogenicity: effects of the TGF alpha transgene. Progress in Clinical and Biological Research, 396:277-31.
48. Guruswamy, S., Lightfoot S., Gold, M. et al. 2001. Effects of retinoids on cancerous phenotype and apoptosis in organotypic culture of ovarian carcinoma. J. Nat. Cancer Inst., 93:516-25.
49. Haranaka, R., Hasegawa, R., Nakagawa, S. et al. 1988. Antitumor activity of combination therapy with traditional Chinese medicine and OK432 or MMC. Journal of Biological Response Modifiers, 7:77-90.
50. Harrl, M., Karagiannidis A.I. and Bister, K. 2006. Cooperative cell transformation by Myc/Mil(Raf) incolves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene, 25:4043-55.
51. Holm, S. 1979. A simple sequentially rejective multiple test procedure. Scand. J. Statistics, 6:65-7.
52. Hoover, H., Muralidharan-Chari, V., Tague, S. et al. 2005. Investigating the role of ADP-ribosylation factor 6 in tumor cell invasion and extracellular signal-regulated kinase activation. Methods in Enzymology, 404:134-47.
53. Hopfer, H., Rinehart, C., Gunter, V. et al. 1994. In vitro interactions of endometrial stromal and epithelial cells in matrigel: reorganization of extracellular matrix. Pathobiol., 62:104-8.
54. Huether, A., Hopfner, M., Sutter, A.P. et al. 2006. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World Journal of Gastroenterology, 12:5160-7.
55. Iavarone C., Catania, A., Marinissen, M.J. et al. 2003. The platelet-derived growth factor controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. Journal of Biological Chemistry, 278:50024-30.
56. Inaba, T., Wiest, W.G., Strickler, R.C. et al. 1988. Augmentation of the response of mouse uterine epithelial cells to estradiol by uterine stroma. Endocrin., 123:1253-8.
57. Ioachim, E., Charchanti, A., Briasoulis, E. et al. 2002. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in turnout invasion and progression. Eur. J. Cancer, 28:2362-70.
58. Ishihara, A., Yoshida, T., Tamaki, H. et al. 1995. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res., 1:1035-41.
59. Ishiwata, T., Takahashi, K., Shimanuki, Y. et al. 2005. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Research, 25:489-95.
60. Jahkola, T., Toivonen, T., Nordling, S. et al. 1998. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur. J Cancer, 34:1687-92.
61. Jarvis, J.N., Dozmorov, I., Jiang, K. et al. 2004a. Gene Expression Arrays Reveal a Rapid Return to Normal Homeostasis in Immunologically-Challenged Trophoblast-Like JAR. Cells. J. Reproduct. Immunol., 61:99-113.
62. Jarvis, J.N., Dozmorov, I., Jiang, K. et al. 2004b. Novel approaches to gene expression analysis of active polvarticular juvenile rheumatoid arthritis. Arthritis. Res. Ther., 6R15R32.
63. Jauliac, S., Lopez-Rodriguez, C., Shaw, L.M. et al. 2002. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nature Cell. Biology, 4:540-4.
64. Jeon, Y.-T., Kang, S., Kang, D.-H. et al. 2004. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiology, Biomarkers and Prevention, 13:1538-42.
65. Jones, H.E., Gee, J.M.W., Taylor, K.M. et al. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer, 12 Suppl 1:S173-82.
66. Jones, P.L., Chapados, R., Baldwin, H.S. et al. 2002. Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung. American Journal of Physiolog - Lung Cellular and Molecular Physiology, 282:L26-35.
67. Kamelle, S., Sienko, A. and Benbrook, D.M. 2002. Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertility and Sterility, 78:596-602.
68. Kenney, M.C., Zorapapel, N., Atilano, S. et al. 2003. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta (TGF-beta) modulate tenascin-C and fibrillin-1 in bullous keratopathy stromal cells in vitro. Experimental Eye Research, 77:537-46.
69. Kirch, H.C., Flaswinkel, S., Rumpf, H. et al. 1999. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene, 18:2728-38.
70. Knowlton, N., Dozmorov, I. and Centola, M.B. 2004. Microarray data analysis toolbox (MDAT) for normalization, adjustment and analysis of gene expression data. Bioinformatics, 20:3687-90.
71. Komori, A., Suganuma, M., Okabe, S. et al. 1993. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor alpha release and of protein isoprenylation. Cancer Research, 53:3462-4.
72. Konopka, B., Janiec-Jankowska, A., Paszko, Z. et al. 2004. The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. Journal of Cancer Research and Clinical Oncology, 130:114-21.
73. Kuefer, R., Day, K.C., Kleer, C.G. et al. 2006. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia (New York), 8:319-29.
74. Lappohn, R.E., Burger, H.G., Bouma, J. et al. 1989. Inhibin as a marker for granulosa-cell tumors. N. Engl. J. Med., 321:790-3.
75. Latijnhouwers, M.A., De Jongh, G.J., Bergers, M. et al. 2000. Expression of tenascin-C splice variants by human skin cells. Archives of Dermatological Research, 292:446-54.
76. Lenertz, L.Y, Lee, B.H., Min, X. et al. 2005. Properties of WNK1 and implications for other family members. Journal of Biological Chemistry, 280:26653-8.
77. Lian, Z., Niwa, K., Gao, J. et al. 2002. Shimotsu-to is the agent in Juzen-taiho-to responsible for the prevention of endometrial carcinogenesis in mice. Cancer Letters, 182:19-26.
78. Liao, D.J., Natarajan, G., Deming, S.L. et al. 2000. Cell. cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Oncogene, 19:1307-17.
79. Lin, C.Y., Strom, A., Vega, V.B. et al. 2004a. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biology, 5:R.66.
80. Lin, C.Y., Strom, A., Vega, V.B. et al. 2004b. Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biology, 51.66.
81. Liu, S., Brown, C.W., Berlin, K.D. et al. 2004. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J. Med. Chem., 47:999-1007.
82. Liu, T.-Z., Hannafon, B., Gill, L. et al. 2007a. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer Ther., 6:1814-22.
83. Liu, T., Masamha, C.P., Chengedza, S. et al. 2007b. Regulation of apoptosis, cell cycle progression and differentiation by SHetA2 in renal cancer cells is associated with alterations in Bcl-2, Cyclin D1 and E-Cadherin proteins. AACR-NCI-EORTC International Conference of Molecular Targets aud Cancer Therapeutics, San Francisco, CA, USA.
84. Liu, Z., Zhang, Y., Hua, Y.F. et al. 2007c. Metabolism of A Sulfur-containing Heteroarotionoid Antitumor Agent, SHetA2, using Liquid Chromatography/tandem Mass Spectrometry. Rapid Communications in Mass Spectrometry. Submitted.
85. Masamha, C.P., Ziu, T. and Benbrook D.M. 2007. SHetA2 targets cyclin DI for proteasoma! degradation through a GSKβ-independent mechanism leading to G1 cell cycle arrest. AACR-A7CI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, San Francisco, CA, USA.
86. Mauri, R, Scarpa, A., Nascimbeni, A.C. etal. 2005. Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB. Journal, 19:1125-7.
87. Mic, F.A., Molotkov, A., Benbrook, D.M. et al. 2003. Retinoid activation of RAR. but not RXR. is sufficient for mouse embryonic development. Proc. Natl. Acad Sci., 100:7135-40.
88. Moore, R.J., Owens, D.M., Stamp, G. et al. 19991. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.[erratum appears in Nat Med 1999 Sep; 5(9):1087]. Nature Medicine, 5:828-31.
89. Mylonas, I., Makovitzky, J., Hoeing, A. et al. 2006. Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB.) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta. Histochemica., 108:1-11.
90. O'neill, E.F., Matallanas, D. and Kolch, W. 2005. Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Research, 65:5485-7.
91. O'toole, S.A., Dunn, E., Sheppard, B.L. et al. 2006. Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays. International Journal of Gynecological Cancer, 16:834-42.
92. Onogi, K., Niwa, K., Tang, L. et al. 2006. Inhibitory effects of Hochu-ekkito on endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol in mice. Oncology Reports, 16:1343-8.
93. Paint: http://www.dbi.tju.edu/dbi/toolspaint
94. Pei, H., Li, C., Adereth, Y. et al. 2005. Caspase-1 is a direct target gene of ETS1 and plays a role in ETS1-induced apoptosis. [erratum appears in Cancer Res. 2005 Dec 1; 65(23):11228]. Cancer Research, 65:7205-13.
95. Ranger-Moore, J., Alberts, D.S., Montironi. R. et al. 2005. Karyometry in the early detection and chemoprevention of intraepithelial lesions. European Journal of Cancer, 41:1875-88.
96. Remacle-Bonnet M., Garrouste, F., Baillat, G. et al. 2005. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-J receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. American Journal of Pathology, 167:761-73.
97. Robertson, D.M., Burger, H.G. and Fuller, P.J. 2004. Inhibin/activin and ovarian cancer. Endocrine-Related Cancer, 11:35-49.
98. Sasaki, M., Nakajima, K., Perinchery, G. et al. 2000, Frequent genotype changes at -308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncology Reports, 7:369-73.
99. Sato, A., Aonuma, K., Imanaka-Yoshida, K. et al. 2006. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. Journal of the American College of Cardiology, 47:2319-25.
100. Scott, K.A., Moore, R.J., Arnott, C.H. et al. 2003. An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Molecular Cancer Therapeutics, 2:445-51.
101. Sedele, M., Karaveli, S., Pestereli, H.E. et al. 2002. Tenascin expression in normal, hyperplastic, and neoplastic endometrium. International Journal of Gynecological Pathology, 21:161-6.
102. Sekbaram. M.. Zhao. H.. Sun. M. et al. 2003. Insulin-like arowth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt(Bcl-x(L) pathwgy. Cancer Research, 63:7708-16.
103. Shi, Y., Ouyang, P. and Sugrue, S.P. 2000. Characterization of the gene encoding pimn/DRS/memA and evidence for its potential tumor suppressor function. Oncogene, 19:289-97.
104. Silverman, A.K., Ellis, C.N. and Voorhees, J.J. 1987. Hypervitaminosis A syndrome: A paradigm of retinoid side effects. J. Am. Acad. Dermatol., 16:1027-39.
105. Steinbach, J.P., Eisenmann, C., Klumpp, A. et al. 2004. Co-inbibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. Biochemical and Biophysical Research Communications, 321:524-30.
106. Sturge, J., Hamelin, J. and Jones, G.E. 2002. N-WASP activation by abetal-integrin-dependent mechanism supports PI3K-independent chemotaxis stimulated by urokinase-type plasminogen activator. Journal of Cell. Science, 115:699-711.
107. Suganuma, M., Okabe, S., Marino, M.W. et al. 1999. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Research, 59:4516-8.
108. Sumantran, V.N. and Feldman, E.L. 1993. Insulin-like growth factorI regulates c-myc and GAP-43 messenger ribonucleic acid expression in SH-SY5Y human neuroblastoma cells. Endocrinology, 132:2017-23.
109. Swindle, C.S., Tran, K.T., Johnson, T.D. et al. 2001. Epidermal growth factor (EGF)-like repeat of human tenascin-C as ligands for EGF receptor. Journal of Cell. Biology, 154:459-68.
110. Tagami, K., Niwa, K., Lian, Z. et al. 2004. Preventive egectof Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent. Biological and Pharmaceutical Bulletin, 27:156-61.
111. Tashiro, E., Tsuchiya, A. and Imoto, M. 2007. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Science, 98:629-35.
112. Todorova, V.K., Kaufmann, Y., Lao, S. et al. 2006. Modulation of p53 and c-myc inIMBA-induced mammary tumors by oral glutamine. Nutrition and Cancer, 54:263-73.
113. Tusher, V.G., Tibshirani, R. and Chu, G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A, 98:5116-21.
114. Vadigepalli, R., Chakravarthula, P., Zak, D.E. et al. 2003. PAINT: a promoter analysis and interaction network generation tool for gene regulatory network identification. OMICS, 7:235-52.
115. Vita, M. and Henriksson, M. 2006. The Myc oncoprotein as a therapeutic target for human cancer. Seminars in Cancer Biology, 16:318-30,
116. Vollmer, G., Tan, M.I., Wunsche, W. et al. 1997. Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: heterogeneity of splice variants and induction by TGF-beta. Biochemistry and Cell. Biology, 75:759-69.
117. Wallner, K., Li, C., Shan, P.K. et al. 2004. EGF-Like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arteriosclerosis, Thrombosis and Vascular Biology, 24:1416-21.
118. Welt, C.K. 2002. The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Current Opinion in Obstetrics and Gynecology, 14:317-23.
119. Wilson, K.E., Langdon, S.P., Lessells, A.M. et al. 1996. Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br. J. Cancer, 74:999-1004.
120. Zacheis, D., Dhar, A., Lu, S. et al. 1999. Heteroarotinoids inhibit the growth of head and neck cancer cell lines in vitro and in vivo through both RAR and RXR. retinoic acid receptors. J. Med. Chem., 42:4434-45.
121. Zeng, P.Y., Rane, N., Du, W. et al. 2003a. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene, 22:1124-34.
122. Zeng, P.Y., Rane, N., Du, W., et al. 2003b. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene., 22:1124-34.
123. Zhaorigetu, S., Yanaka, N., Sasaki, M. et al. 2003. Silk protein, sericin, suppresses DMBA-TRA-induced mouse skin tumorigenesis by reducing oxidative stress, inflammatory responses and endogenous tumor promoter TNF-alpha. Oncology Reports, 10:537-43.